Ki67 assessment in breast cancer: an update-Reference-Cited by-同舟云学术

Ki67 assessment in breast cancer: an update

Published:2017-02 Issue:2 Volume:49 Page:166-171
ISSN:0031-3025
Container-title:Pathology
language:en
Short-container-title:Pathology

Author:

Penault-Llorca Frederique,Radosevic-Robin Nina

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference37 articles.

1. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation;Gerdes;Int J Cancer,1983

2. Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67;Duchrow;Cell Prolif,1996

3. Current breast cancer proliferative markers correlate variably based on decoupled duration of cell cycle phases;Lee;Sci Rep,2014

4. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group;Dowsett;J Natl Cancer Inst,2011

5. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version);Hammond;Arch Pathol Lab Med,2010

Cited by 161 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ultrasound-based radiomics nomogram for distinguishing invasive breast cancer (IBC) from invasive breast cancer with intraductal component (IBC-IC);Journal of Radiation Research and Applied Sciences;2024-09

2. Mechanisms of Yiai Fuzheng formula in the treatment of triple-negative breast cancer based on UPLC-Q-Orbitrap-HRMS, network pharmacology, and experimental validation;Heliyon;2024-09

3. Advancing Ki67 hotspot detection in breast cancer: a comparative analysis of automated digital image analysis algorithms;Histopathology;2024-08-05

4. Pathological Changes Following Neoadjuvant Endocrine Therapy (NAET): A Multicentre Study of 391 Breast Cancers;International Journal of Molecular Sciences;2024-07-05

5. Development and Validation of a Prognostic Nomogram for HR+ HER- Breast Cancer;Cancer Management and Research;2024-05